Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 5

Overall survival rates categorized by HER2 status and adjuvant therapy.

	3-year OS	5-year OS	6-year OS	7-year OS
HER2 positive
Trastuzumab + CHT+ AHT	97%	96%	96%	96%
CHT + AHT	98%	98%	92%	92%
Trastuzumab + CHT	95%	92%	92%	86%
CHT	82%	65%	65%	65%
AHT	91%	83%	79%	79%
No adjuvant therapy	75%	63%	55%	55%
HER2 negative
CHT + AHT	98%	95%	93%	92%
CHT	89%	86%	83%	83%
AHT	95%	90%	88%	88%
No adjuvant therapy	81%	75%	73%	64%